ALIKO.PA Ikonisys SA
- Market cap
- EUR 22.2M
- P/E
- -
- P/B
- 1.21x
- ROE
- -22.0%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ALIKO.PA undervalued?
Graham numberThe Graham number of Ikonisys SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ikonisys SA fundamental analysis
3 of 11 checks passedROE 0/2
The stock's ROE indicates a negative return (-13.3%) on shareholders' equity, suggesting poor financial performance.
ROA 0/2
The stock's ROA (-237.17%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.
PBV 2/2
With a remarkably low PBV ratio (0.75x), the stock offers substantial upside potential at a bargain price.
DER 2/2
The stock has a minimal amount of debt (14%) relative to its ownership, showcasing a strong financial position and lower risk for investors.
Revenue Growth 0/2
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.
Net Profit Growth 0/2
Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.
Assets Growth 0/2
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.
Graham Number 1/1
The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.
Dividend Growth 0/2
Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.
Dividend 0/2
The company's lack of dividends in the past three years may concern investors seeking regular income.
Buffet Intrinsic Value 0/1
The company's stock appears overvalued (-1) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Ikonisys SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ikonisys SA
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that a…
Full company profileIkonisys SA financial statements
Ikonisys SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 68.4K | 99.8K | 365K | 935K | 449K | 1.01M | 1.39M |
| Gross Profit | 4.75K | 72.8K | 28.5K | 752K | 256K | 715K | 897K |
| Operating Income | -251K | 205K | -564K | -2.64M | -2.19M | -3.05M | -4.04M |
| EBITDA | -180K | 273K | -484K | -1.35M | -927K | -1.77M | -1.28M |
| Net Income | -1.88M | -1.57M | -571K | -2.45M | -2.27M | -3.24M | -4.20M |
| EPS | -0.19 | -0.16 | -0.06 | -0.26 | -0.22 | -0.29 | -0.30 |
| Balance Sheet | |||||||
| Total Assets | 8.13M | 8.08M | 22.5M | 21.7M | 20.9M | 27.4M | 26.7M |
| Total Liabilities | 2.04M | 2.39M | 2.50M | 4.04M | 5.12M | 13.1M | 7.58M |
| Shareholders' Equity | 6.09M | 5.70M | 20.0M | 17.7M | 15.7M | 14.3M | 19.1M |
| Cash & Short-term Investments | 173K | 37.6K | 1.52M | 94.0K | 9.40K | 25.1K | 1.03M |
| Total Debt | 297K | 198K | 1.24M | 2.51M | 3.40M | 4.13M | 3.25M |
| Cash Flow | |||||||
| Operating Cash Flow | - | -1.52M | -781K | -1.14M | -914K | -1.33M | -1.16M |
| Capital Expenditure | 0.00 | 0.00 | 576K | 875K | 542K | 37.9K | 9.09K |
| Free Cash Flow | - | -1.52M | -1.36M | -2.01M | -1.46M | -1.37M | -1.17M |
| Ratios | |||||||
| ROE | -30.9% | -27.6% | -2.9% | -13.9% | -14.4% | -22.7% | -22.0% |
| ROA | -23.1% | -19.4% | -2.5% | -11.3% | -10.9% | -11.8% | -15.7% |
| Net Profit Margin | -2,745.6% | -1,575.0% | -156.5% | -261.8% | -505.5% | -320.4% | -302.8% |
| Debt to Equity | 0.05x | 0.03x | 0.06x | 0.14x | 0.22x | 0.29x | 0.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ikonisys SA dividends
Ikonisys SA has not paid dividends in the last 7 fiscal years.
Who owns Ikonisys SA
- Insiders 17.79%
- Institutions 45.42%
- Public & others 36.79%
- Shares outstanding 15.8M
- Free float 7.18M
Ikonisys SA company profile
- Company name
- Ikonisys SA
- Ticker
- ALIKO.PA
- ISIN
- FR00140048X2
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 15
- Fiscal year end
- December
- Address
- 62 rue de Caumartin, Paris, France, 75009
- Phone
- 33 39 348 901 9064
- Website
- ikonisys.com
About Ikonisys SA
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that allows scanning and analysis of cells from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of gene rearrangements commonly associated with non-small cell lung carcinoma; oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene, which is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems. In addition, it offers liquid biopsy/CTC bladder cancer detection and breast cancer early diagnostics products; CYTOfast vial solution for any type of cellular analysis; CYTOfast kit urine, a three day cytological urine test solution; CYTOfast PLUS, a liquid-phase processor that prepares thin-layer cytological samples from liquid-phase specimen; and Ikonisys intelligent application, a software designed to automatically quantify, qualify, and present cells for review and streamlining the diagnostic process. Ikonisys S.A. was incorporated in 2021 and is headquartered in Paris, France.
Ikonisys SA management
4- Mr. Francesco TrisoliniChief Executive Officer
- Dr. Michael W. Kilpatrick Ph.D.Founder & CSO
- Mr. Alessandro MauriChief Financial Officer
- Mr. Jurgen SchipperSales Director